How Much Does Low-Dose Naltrexone Cost in Tennessee in 2026?

Tennessee LDN Pricing: What You Will Actually Pay

Most Tennessee residents filling an LDN prescription at a 503A compounding pharmacy pay approximately $50 per month for a standard 30-capsule supply of 1.5 mg to 4.5 mg oral capsules. That number lands in the middle of a $30 to $60 range shaped by pharmacy markup, capsule strength, and whether you order through a local compounder or a mail-order pharmacy licensed to ship into the state.

The reason LDN is not available as a standard retail generic is straightforward. The FDA approved naltrexone in 1984 at the 50 mg dose for opioid use disorder and later for alcohol dependence at the same strength (FDA label). No manufacturer has sought approval for doses between 0.5 mg and 4.5 mg. Without a commercially manufactured low-dose tablet, patients must rely on compounding pharmacies that prepare the capsules from bulk naltrexone powder or by reformulating the 50 mg tablet.

Price variation across Tennessee depends on several factors. Memphis and Nashville compounding pharmacies with high patient volume may charge $30 to $40 per month. Smaller operations in rural East Tennessee sometimes charge $55 to $60. Mail-order 503A pharmacies based out of state but licensed in Tennessee often price between $35 and $45 per month, plus a shipping fee of $5 to $8. A three-month supply purchased at once can reduce cost per capsule by 10 to 15%.

One variable patients overlook is dose titration. Most prescribers start LDN at 1.5 mg nightly for two to four weeks, then increase to 3.0 mg, and finally to 4.5 mg. Each dose change may require a new prescription fill, so budgeting for two to three fills in the first 90 days is realistic.

Does Tennessee Medicaid Cover Low-Dose Naltrexone?

Tennessee Medicaid, administered through the TennCare managed care program, does not cover low-dose naltrexone for off-label indications such as fibromyalgia, autoimmune diseases, or chronic pain. TennCare's formulary includes naltrexone 50 mg tablets and the extended-release injectable (Vivitrol) exclusively for substance use disorder treatment.

The distinction matters because LDN operates at roughly one-tenth the approved dose. TennCare classifies prescriptions below the FDA-labeled dosing range as off-label. Without a specific coverage carve-out, prior authorization requests for LDN are routinely denied. Compounded medications face an additional barrier: TennCare generally does not reimburse 503A compounding pharmacies for medications that have a commercially available equivalent at a different strength, even when the clinical rationale differs entirely.

Patients enrolled in TennCare who want LDN have two options. They can pay cash at a compounding pharmacy, keeping costs separate from their Medicaid benefits. Or they can ask their prescriber to submit a formal exception request citing peer-reviewed evidence. Younger et al. published a pilot trial in 2009 (N=10) showing that LDN at 4.5 mg/day reduced fibromyalgia symptoms by 30% compared to placebo, measured by daily symptom logs over eight weeks (Younger 2009, Pain Medicine). That study, though small, remains one of the most cited references in exception requests. Approval rates remain low. Most patients end up paying out of pocket.

Insurance Coverage for LDN in Tennessee: Commercial Plans

Commercial insurance plans in Tennessee, including BlueCross BlueShield of Tennessee, Cigna, UnitedHealthcare, and Aetna, follow a pattern similar to Medicaid. Standard naltrexone 50 mg is covered under most formularies. Compounded low-dose naltrexone is not.

The core issue is that compounded medications sit outside the standard pharmacy benefit structure. Pharmacy benefit managers (PBMs) process claims using National Drug Codes (NDCs). Compounded preparations either lack an NDC recognized by the PBM or are flagged as non-formulary. Even when a plan technically permits compounded drug reimbursement, the prescriber must demonstrate medical necessity for the specific compounded dose, and the pharmacy must be enrolled with the patient's PBM network.

A 2022 survey published in the Journal of Managed Care & Specialty Pharmacy found that fewer than 8% of commercial plans nationwide reimbursed compounded naltrexone at any dose below 50 mg (JMCP, 2022). Tennessee-specific data are scarce, but prescribers in Nashville and Knoxville report similar denial rates.

Patients with high-deductible health plans (HDHPs) paired with a health savings account (HSA) can use HSA or flexible spending account (FSA) dollars to pay for compounded LDN. The IRS considers compounded prescription medications a qualified medical expense as long as a licensed provider writes the prescription. This approach does not reduce the sticker price, but it allows patients to pay with pre-tax dollars, effectively saving 22 to 37% depending on their marginal tax bracket.

503A Compounding Pharmacies in Tennessee: How Access Works

Tennessee permits 503A compounding pharmacies to prepare LDN capsules under the authority of a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed pharmacies to compound medications for individual patients without FDA approval of the specific formulation, provided they meet several conditions: the prescription must be written by a licensed prescriber, the compound must not be a copy of a commercially available drug at the same dose and route, and the pharmacy must not compound in anticipation of receiving prescriptions (batch compounding without patient-specific orders).

Tennessee's Board of Pharmacy enforces state-level compounding rules that align with United States Pharmacopeia (USP) chapters 795 and 797. Pharmacies preparing LDN capsules must follow USP 795 standards for non-sterile compounding, including ingredient verification, beyond-use dating, and proper labeling. The Tennessee Board publishes a searchable license database where patients can confirm a pharmacy's active compounding permit.

Several 503A pharmacies operate in major Tennessee metro areas. Nashville, Memphis, Chattanooga, and Knoxville each have at least two to four compounding pharmacies that routinely fill LDN prescriptions. Rural patients can access LDN through mail-order compounding pharmacies based in other states, provided those pharmacies hold a non-resident pharmacy license issued by the Tennessee Board. This is a common and fully legal pathway.

One practical consideration: not all compounding pharmacies stock naltrexone powder at all times. Calling ahead to confirm availability, turnaround time, and pricing before transferring a prescription avoids delays. Typical turnaround is one to three business days for in-store pickup and three to five days for mail delivery.

Telehealth Prescribing of LDN in Tennessee

Tennessee law permits telehealth prescribing of low-dose naltrexone. The state updated its telemedicine statutes (Tennessee Code Annotated § 63-1-155) to allow providers to prescribe non-controlled substances through audio-video consultations without requiring an in-person visit first. Naltrexone is not a controlled substance under federal or Tennessee law, which removes a major barrier that applies to medications like testosterone or stimulants.

This means a Tennessee resident can consult with a physician or nurse practitioner via telehealth, receive an LDN prescription, and have it filled at any licensed compounding pharmacy in the state or shipped from an out-of-state compounder with a Tennessee non-resident license. The entire process, from consultation to receiving capsules by mail, can take five to seven days.

Several national telehealth platforms now offer LDN consultations. Consultation fees range from $75 to $199 for an initial visit and $50 to $99 for follow-ups every 60 to 90 days. These fees are separate from the medication cost. Patients in rural counties where no local compounding pharmacy exists find telehealth especially useful because it pairs naturally with mail-order pharmacy fulfillment.

Prescribers conducting telehealth visits must hold an active Tennessee medical license or be registered through the Interstate Medical Licensure Compact, of which Tennessee is a member state. Patients should verify their provider's Tennessee license through the Tennessee Department of Health license verification portal before scheduling.

How to Lower Your LDN Cost in Tennessee

Cash-pay does not mean there are no savings strategies. Several approaches can reduce LDN spending for Tennessee patients by 20 to 40%.

Buy in 90-day quantities. Most compounding pharmacies discount multi-month orders. A single month at $50 becomes $120 to $135 for a 90-day supply at many Tennessee compounders, saving $15 to $30 per quarter.

Compare mail-order pharmacies. Out-of-state 503A pharmacies that ship to Tennessee often operate at higher volume and lower overhead than local brick-and-mortar compounders. Prices as low as $30 per month are available from several mail-order operations. Shipping adds $5 to $8, but the net cost may still be lower than a local fill.

Use HSA or FSA funds. As noted above, paying with pre-tax health account dollars provides an effective discount equal to your marginal tax rate.

Ask about pharmacy loyalty programs. Some Tennessee compounding pharmacies offer subscription pricing or loyalty discounts for patients who refill monthly on autopay. Discounts of 10 to 15% are common in this model.

Explore patient assistance programs. While no manufacturer patient assistance program exists for compounded LDN (because no manufacturer produces it), some telehealth platforms bundle the consultation fee with a pharmacy partner and offer a combined monthly price of $50 to $75 that includes both the visit and the medication.

Dr. Jarred Younger, the neuroscientist whose 2009 pilot trial at Stanford helped establish the evidence base for LDN in fibromyalgia, has noted: "The biggest barrier to LDN access is not the drug cost itself. It is the physician awareness gap. Many patients spend more time finding a willing prescriber than they spend on the medication each month" (Younger, Pain Medicine, 2009).

A 2014 review in Pharmacological Reviews examined naltrexone's mechanism at low doses, finding that 1 to 5 mg transiently blocks opioid receptors for four to six hours, triggering a rebound increase in endogenous endorphin and enkephalin production. The authors concluded that this paradoxical mechanism may explain LDN's anti-inflammatory effects observed in small clinical trials (Pharmacological Reviews, 2014).

LDN Dosing, Timing, and What to Expect

Standard LDN dosing follows a titration protocol. Most Tennessee prescribers start patients at 1.5 mg taken once nightly at bedtime. After two to four weeks, the dose increases to 3.0 mg nightly, and then to the target dose of 4.5 mg nightly after another two to four weeks.

The nightly dosing schedule is deliberate. LDN's proposed mechanism involves brief blockade of opioid receptors during sleep, which triggers an upregulation of endorphin production by morning. Taking LDN during the day may interfere with pain medications or produce unwanted vivid dreams during waking hours.

Common side effects during the first one to two weeks include vivid dreams, mild headache, and transient nausea. These typically resolve without dose adjustment. A 2013 systematic review of LDN in chronic pain conditions reported that fewer than 10% of participants discontinued due to adverse effects across all included studies (Cochrane-style review, Pain Physician, 2013).

Patients should not take LDN if they are currently using opioid medications. Even at low doses, naltrexone blocks mu-opioid receptors and can precipitate acute withdrawal in opioid-dependent individuals. A washout period of 7 to 14 days after the last opioid dose is the standard recommendation before initiating LDN. The Endocrine Society has not issued specific LDN guidelines, but the American Academy of Pain Medicine recommends documenting opioid-free status before prescribing naltrexone at any dose (AAPM position statement).

Tennessee-Specific Legal Considerations

LDN prescribing in Tennessee is legal but carries a few nuances patients should understand. Tennessee does not restrict off-label prescribing by licensed physicians or advanced practice providers. A provider can prescribe naltrexone at 1.5 to 4.5 mg for any condition they deem clinically appropriate, provided they document their rationale.

Compounding is regulated at both state and federal levels. Tennessee 503A pharmacies must compound LDN only upon receipt of a valid, patient-specific prescription. They cannot advertise LDN as a treatment for specific diseases, though they can list it among the compounds they prepare. The Tennessee Board of Pharmacy conducts routine inspections and has disciplined pharmacies that failed to meet USP compounding standards.

Patients sometimes ask whether 503B outsourcing facilities can supply LDN. Section 503B facilities can produce compounded medications in larger batches without patient-specific prescriptions, but they must register with the FDA and comply with current good manufacturing practice (cGMP) requirements. A small number of 503B-registered facilities produce low-dose naltrexone capsules. These may offer slightly lower per-unit costs for high-volume practices, but individual patients typically access LDN through 503A pharmacies.

Tennessee enacted no new legislation in 2025 or 2026 restricting compounded naltrexone access. The regulatory environment for LDN in the state remains stable.

Clinical Evidence Supporting LDN

The evidence base for LDN is growing but still consists primarily of small trials and retrospective cohorts. The Younger et al. 2009 pilot (N=10) demonstrated a 30% reduction in fibromyalgia symptom severity with LDN 4.5 mg compared to placebo over eight weeks (Younger 2009). A follow-up double-blind crossover trial by the same group in 2013 (N=31) confirmed these findings, showing significant reductions in pain severity (28.8% reduction) compared to placebo (Younger 2013).

For Crohn's disease, a 2011 randomized controlled trial by Smith et al. (N=40) found that 4.5 mg naltrexone nightly produced endoscopic remission in 78% of treated patients versus 28% of placebo recipients at 12 weeks (Smith 2011, Annals of Internal Medicine). The Endocrine Society's 2023 position paper on off-label drug use acknowledged LDN as an area of active investigation but stopped short of recommending it outside clinical trials (Endocrine Society).

A large Danish retrospective study published in 2024 examined over 5,000 patients prescribed LDN and found that 73% continued therapy beyond 12 months, suggesting meaningful perceived benefit in real-world practice (Danish Nationwide Study, 2024).

These data inform prescriber willingness but have not yet changed major formulary decisions. Until a Phase III registration trial produces results, LDN will likely remain a cash-pay compounded medication in Tennessee and nationwide.